Effects of lornoxicam on the physiology of severe sepsis

Basit Öğe Kaydı
dc.contributor.authorMemis, D
dc.contributor.authorKaramanlioglu, B
dc.contributor.authorTuran, A
dc.contributor.authorKoyuncu, O
dc.contributor.authorPamukçu, Z
dc.date.accessioned2024-06-12T10:54:36Z
dc.date.available2024-06-12T10:54:36Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction The purpose of the present study was to evaluate the effects of intravenous lornoxicam on haemodynamic and biochemical parameters, serum cytokine levels and patient outcomes in severe sepsis. Methods A total of 40 patients with severe sepsis were included, and were randomly assigned ( 20 per group) to receive either lornoxicam ( 8 mg administered intravenously every 12 hours for six doses) or placebo. For both groups the following were recorded: haemodynamic parameters ( heart rate, mean arterial pressure), nasopharyngeal body temperature, arterial blood gas changes ( pH, partial oxygen tension, partial carbon dioxide tension), plasma cytokine levels (IL-1beta, IL-2 receptor, IL-6, IL-8, tumour necrosis factor-alpha), biochemical parameters ( lactate, leucocytes, trombocytes, creatinine, total bilirubin, serum glutamate oxalate transaminase), length of stay in the intensive care unit, duration of mechanical ventilation and mortality. All measurements were obtained at baseline ( before the start of the study) and at 24, 48 and 72 hours from the start of lornoxicam/placebo administration. Results No significant differences were found between the intravenous lornoxicam and placebo groups in major cytokines, duration of ventilation and length of intensive care unit stay, and inspired fractional oxygen/arterial oxygen tension ratio ( P > 0.05). Conclusion In these patients with severe sepsis, we found intravenous lornoxicam to exert no effect on haemodynamic and biochemical parameters, cytokine levels, or patient outcomes. Because of the small number of patients included in the study and the short period of observation, these findings require confirmation by larger clinical trials of intravenous lornoxicam, administered in a dose titrated manner.en_US
dc.identifier.doi10.1186/cc2969
dc.identifier.endpageR482en_US
dc.identifier.issn1466-609X
dc.identifier.issn1364-8535
dc.identifier.issue6en_US
dc.identifier.pmid15566594en_US
dc.identifier.startpageR474en_US
dc.identifier.urihttps://doi.org/10.1186/cc2969
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19099
dc.identifier.volume8en_US
dc.identifier.wosWOS:000226232100018en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofCritical Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiochemical Parametersen_US
dc.subjectCytokine Levelsen_US
dc.subjectHaemodynamic Parametersen_US
dc.subjectIntensive Care Uniten_US
dc.subjectLornoxicamen_US
dc.subjectOutcomeen_US
dc.subjectSevere Sepsisen_US
dc.subjectSurvivalen_US
dc.subjectInhibitoren_US
dc.subjectIbuprofenen_US
dc.subjectProstaglandinsen_US
dc.subjectProstacyclinen_US
dc.subjectCytokinesen_US
dc.subjectNsaiden_US
dc.titleEffects of lornoxicam on the physiology of severe sepsisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu